Measurable Residual Disease in IDH-Mutated AML: Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring.
A blood test measuring IDH mutations may help predict outcomes in certain leukemia patients, guiding treatment monitoring decisions.
METHODS, We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single-center cohort of patients with IDH-mutated AML treated with curative intent. CONCLUSIONS, A 0,2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH-based MRD assessment in AML.
What the study was
- Study design
- Prospective biomarker cohort / analytical validation
- Population
- patients
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- European journal of haematology
Why it surfaced
Abstract-reviewed prospective biomarker cohort / analytical validation scored conservatively for genomics/precision medicine; 8/10 reflects the available design, relevance, novelty, and population or unmet-need evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.